Skip to main
DRRX
DRRX logo

DURECT (DRRX) Stock Forecast & Price Target

DURECT (DRRX) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 20%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Durect Corp's pipeline, particularly the larsucosterol product, demonstrates promising potential for clinically meaningful mortality reductions, with notable trends indicating a 41% reduction in the 30 mg dose group and a 35% reduction in the 90 mg dose group at 90 days. The company's strategic management plans to initiate a Phase 3 trial for larsucosterol upon securing funding, which highlights their commitment to advancing this key asset. Furthermore, Durect intends to explore new partnership opportunities for POSIMIR once it regains rights, indicating operational strategies that could enhance future revenue streams and bolster overall financial health.

Bears say

Durect Corp reported a net loss of $4.3 million for the third quarter of 2024, with operating expenses comprising $2.2 million in research and development and $3.2 million in general and administrative costs. The company faces significant "going concern" risks due to its cash runway, which is projected to last only through early 2025, raising concerns about its financial sustainability in the near term. Moreover, uncertainties regarding the financing of the Phase 3 trial for larsucosterol and challenges related to the study's design have further compounded the negative outlook for the company's future growth prospects.

DURECT (DRRX) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 20% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DURECT and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DURECT (DRRX) Forecast

Analysts have given DURECT (DRRX) a Strong Buy based on their latest research and market trends.

According to 10 analysts, DURECT (DRRX) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DURECT (DRRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.